Loading organizations...
§ Venture Capital · Boston, MA, USA
Invests in novel therapeutics, medical devices, diagnostics, and drug delivery systems with a focus on unmet need, clinical impact, and proprietary science.
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates.
Key people at Novartis Venture Fund.
Novartis Venture Fund is a strategic investment arm of Novartis that focuses on investing in novel therapeutics, medical devices, diagnostics, and drug delivery systems with an emphasis on addressing unmet medical needs, clinical impact, and proprietary science. Its mission is to foster innovation in life sciences by supporting companies that develop breakthrough therapies and platforms, aiming to improve patient outcomes globally while generating superior returns. The fund primarily invests in biotechnology and biopharmaceutical startups across North America, Europe, and Israel, managing over USD 750 million in committed capital and maintaining a portfolio of more than 40 companies. It actively supports startups from early stages through clinical milestones, providing not only capital but also strategic guidance and board involvement to accelerate growth and clinical success[1][2][3][6].
Founded as part of Novartis’s broader innovation strategy, the fund was established to bridge the gap between early scientific discovery and commercial application in healthcare. Key leaders include Anja Koenig (Global Head) and several managing directors who bring deep expertise in venture investing and pharma. The fund’s evolution reflects a growing focus on precision medicine, immunology, oncology, and digital health, aligning with Novartis’s core therapeutic areas. This approach allows the fund to leverage Novartis’s global network and scientific resources while nurturing local innovation hubs and startups with disruptive technologies[2][1].
Novartis Venture Fund rides the wave of precision medicine, biologics, and digital health innovation, sectors experiencing rapid scientific and technological advances. The timing is critical as healthcare increasingly demands targeted therapies and integrated diagnostics to address complex diseases more effectively. Market forces such as rising R&D costs, regulatory complexity, and patient-centric care models favor venture-backed innovation that can de-risk early-stage science and accelerate clinical translation. By bridging pharma and startup ecosystems, the fund influences the broader life sciences landscape, fostering collaboration and speeding the delivery of novel treatments to patients[1][2].
Looking ahead, Novartis Venture Fund is poised to deepen its investments in next-generation therapeutics such as targeted protein degradation, gene editing, and immune modulation, while expanding digital health and diagnostic platforms that enhance personalized care. Trends like AI-driven drug discovery and real-world evidence integration will likely shape its portfolio strategy. As the fund continues to leverage Novartis’s global reach and scientific expertise, its influence on the biotech startup ecosystem and patient care innovation is expected to grow, reinforcing its role as a key catalyst in life sciences innovation[2][1].
Key people at Novartis Venture Fund.
Novartis Venture Fund has more than 26 tracked investments across 24 companies. The latest tracked deal is $120.0M Series D in Artios Pharma in November 2025.
